Emergence and infectious complications of ciprofloxacin-resistantEscherichia coli in haematological cancer patients

1998 ◽  
Vol 17 (8) ◽  
pp. 591-592 ◽  
Author(s):  
M. G. J. Kraaij ◽  
A. W. Dekker ◽  
E. Peters ◽  
A. Fluit ◽  
L. F. Verdonck ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Infectious Complications ◽  
Haematological Cancer

Emergence and Infectious Complications of Ciprofloxacin-Resistant Escherichia coli in Haematological Cancer Patients

1998 ◽  
Vol 17 (8) ◽  
pp. 591-592 ◽  
Author(s):  
M. G. J. van Kraaij ◽  
A. W. Dekker ◽  
E. Peters ◽  
A. Fluit ◽  
L. F. Verdonck ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Cancer Patients ◽  
Infectious Complications ◽  
Haematological Cancer

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

2018 ◽  
Vol 76 (1) ◽  
pp. 20-37 ◽  
Author(s):  
Malgorzata Mikulska ◽  
Diana Averbuch ◽  
Frederic Tissot ◽  
Catherine Cordonnier ◽  
Murat Akova ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Critical Appraisal ◽  
Haematological Cancer ◽  
Fluoroquinolone Prophylaxis

scholarly journals INFECTIOUS COMPLICATIONS CAUSED BY NON-SPOREFORMING ANAEROBIC BACTERIA IN CANCER PATIENTS. RELEVANCE OF THE PROBLEM

2020 ◽  
Vol 19 (4) ◽  
pp. 146-151
Author(s):  
I. V. Tereshchenko ◽  
Z. V. Grigoryevskaya ◽  
I. N. Petukhova ◽  
N. S. Bagirova ◽  
V. D. Vinnikova ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Anaerobic Bacteria ◽  
Infectious Complications

scholarly journals The Optimal Time of Applying Enteral Immunonutrition in Esophageal Cancer Patients Receiving Esophagectomy: A Network Meta-Analysis of Randomized Clinical Trials

2021 ◽  
Author(s):  
Xu Tian ◽  
Yan-Fei Jin ◽  
Zhao-Li Zhang ◽  
Hui Chen ◽  
Wei-Qing Chen ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Infectious Complications ◽  
Cochrane Library ◽  
Optimal Time ◽  
Registration Number ◽  
Meta Analyses ◽  
The Impact

Abstract Background: Enteral immunonutrition (EIN) has been extensively applied in cancer patients, however its role in esophageal cancer (EC) patients receiving esophagectomy remains unclear. We performed this network meta-analysis to investigate the impact of EIN on patients undergoing surgery for EC and further determine the optimal time of applying EIN.Methods: We searched PubMed, EMBASE, Cochrane library, and China National Knowledgement Infrastructure (CNKI) to identify eligible studies. Categorical data was expressed as the odds ratio with 95% confidence interval (CI), and continuous data was expressed as mean difference (MD) with 95% CI. Pair-wise and network meta-analysis was performed to evaluate the impact of EIN on clinical outcomes using RevMan 5.3 and ADDIS V.1.16.8 softwares. The surface under the cumulative ranking curve (SUCRA) was calculated to rank all nutritional regimes.Results: Total 14 studies involving 1071 patients were included. Pair-wise meta-analysis indicated no difference between EIN regardless of the application time and standard EN (SEN), however subgroup analyses found that postoperative EIN was associated with decreased incidence of total infectious complications (OR=0.47; 95%CI=0.26 to 0.84; p=0.01) and pneumonia (OR=0.47; 95%CI=0.25 to 0.90; p=0.02) and shortened LOH (MD=-1.01; 95%CI=-1.44 to -0.57; p<0.001) compared to SEN, which were all supported by network meta-analyses. Ranking probability analysis further indicated that postoperative EIN has the highest probability of being the optimal option in terms of these three outcomes.Conclusions: Postoperative EIN should be preferentially utilized in EC patients undergoing esophagectomy because it has optimal potential of decreasing the risk of total infectious complications and pneumonia and shortening LOH.OSF registration number: 10.17605/OSF.IO/KJ9UY.

Serum Procalcitonin Levels Are Elevated in Esophageal Cancer Patients with Postoperative Infectious Complications

2005 ◽  
Vol 37 (1) ◽  
pp. 22-28 ◽  
Author(s):  
S. Ito ◽  
N. Sato ◽  
M. Kojika ◽  
Y. Yaegashi ◽  
Y. Suzuki ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Infectious Complications

Improving the efficiency of the postoperative period in the surgical treatment cancer patients with metastatic bone fractures upper and lower extremities using elixir altai ("vitavis") in combination with ion-activated water resources

10.12737/6454 ◽  
2014 ◽  
Vol 8 (1) ◽  
pp. 0-0
Author(s):  
Антонов ◽  
A. Antonov
Keyword(s):  
Quality Of Life ◽  
Surgical Treatment ◽  
Postoperative Complications ◽  
Cancer Patients ◽  
Postoperative Period ◽  
Bone Fractures ◽  
Infectious Complications ◽  
Lower Limbs ◽  
Oncologic Patients

Use elixir Altai (&#34;Vitavis&#34;) in combination with ion-activated with water by means of such a complex contingent cancer patients as patients with metastatic bone fractures of the upper and lower limbs can reduce the early postoperative period, and to reduce to a minimum infectious complications and improve quality of life. The problem of postoperative complications, until now, is not solved. In oncologic patients, and those more in by III and As IV stages occurs it immunnodefitsit, which is caused not only by basic disease, but also by conse-quences of khimio- beam therapy. In connection with this appears the difficulty in the surgical treatment, caused by postoperative complications. As a result surgical treatment appears surgical injury, oxidizing stress, disturbance of homeostasis and oppression of immunity, which leads to an even larger disturbance of immunity in oncologic patients, which decreases the unspecific resistibility of organism. The application of adaptogena of the elixir of Altai (“Vitavis”) in combination with the ionic- activated aqueous means makes it possible to level and to reduce on no oxidizing stress, to increase the unspecific resistibility of the organism of oncologic patient and to increase immuni-ty. Moreover, powerful antioxidant - the ionic- activated aqueous means strengthens the action of adaptogena of the elixer of Altai (“Vitavis”), which leads to the decrease of postoperative infectious complications, reduces postoperative period, improves the quality of life and enlarges indications to the surgical treatment in oncologic patients with III it and IV by the stages of diseases.

scholarly journals On-line information and support for supporters and carers of haematological cancer patients: is access an issue?

2012 ◽  
Vol 20 (11) ◽  
pp. 2687-2695 ◽  
Author(s):  
Christine L. Paul ◽  
Tara Clinton-McHarg ◽  
Marita Lynagh ◽  
Robert W. Sanson-Fisher ◽  
Flora Tzelepis
Keyword(s):  
Cancer Patients ◽  
Haematological Cancer ◽  
On Line

scholarly journals The importance of developing new mannan tests in the diagnosis of invasive candidiasis in oncology patients

2021 ◽  
Vol 2 (3) ◽  
pp. 42-47
Author(s):  
O. Yu. Kutsevalova ◽  
Yu. Yu. Kozel ◽  
N. E. Nifantiev ◽  
A. V. Antonets ◽  
V. B. Krylov
Keyword(s):  
Cancer Patients ◽  
Invasive Candidiasis ◽  
Clinical Signs ◽  
Anticancer Therapy ◽  
High Dose Chemotherapy ◽  
Infectious Complications ◽  
High Dose ◽  
Life Study ◽  
Invasive Mycosis

The regimens of anticancer therapy have been intensified and methods of high-dose chemotherapy (HDCT) have been introduced for recent years which made it possible to achieve significant progress in the results of tumor treatments. Intensification of chemotherapy regimens in cancer patients leads to the emergence of risk factors of invasive candidiasis (IC) development: agranulocytosis, disruption of the integrity of the mucous membranes, prolonged use of CVC, repeated antibiotic therapy, long-term parenteral nutrition. Thus, intensification of anticancer therapy may be accompanied by an increase in infection-mediated mortality.IC is the most common invasive mycosis in Russia. More than 11 thousand cases of IC occur in our country every year. The frequency IC in Russia is 8.29 per 100 thousand of the population, which corresponds to the results of the LIFE study in European countries where this indicator varies from 2.2 to 11 per 100 thousand of the population. There are no clinical signs or symptoms specific for IC. It develops in patients with concomitant diseases, which significantly complicates the diagnosis. In this regard, an urgent issue is to improve the diagnosis of candidal infectious complications in cancer patients in order to optimize treatment by studying serological markers that have the greatest value in the diagnosis of infectious complications in cancer patients.

Sign in / Sign up

Export Citation Format

Share Document